Is heparanase expression in human leukemias restricted to acute myeloid leukemias?
We propose that heparanase expression is associated with the myeloid lineage and may serve as an independent marker to support the identification of AMLs.
Although the combination therapy group demonstrated a significant RFS advantage, the intravesical therapy regimen did not independently modulate this benefit. Further investigation is warranted to determine if immediate MMC prior to a course of induction BCG confers a benefit to RFS. Nevertheless, this pilot investigation sets an important precedent on the management of NMI bladder cancer, nonwithstanding the absence of contemporary large scale, randomized trials.